Silo Pharma announces roster of drugs in development for mental health, chronic pain

Key takeaways:

• Silo Pharma plans to advance four investigational drugs targeting PTSD, fibromyalgia, Alzheimer’s disease and MS.
• The company aims to gain approval through the FDA’s 505(b)(2) pathway.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.

According to a company release, SPC-15, the company’s lead program, is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder. It is currently being evaluated in a dose-ranging study, with a final validation report anticipated in the first half of 2024.

Another candidate, SP-26, is a nonopioid chronic pain solution under development as a self-administered subcutaneous injectable and dissolvable time-release ketamine-loaded implant for fibromyalgia.

Silo’s collaboration with Columbia University yielded SPC-14, a prospective Alzheimer’s disease therapeutic, while a partnership with the University of Maryland, Baltimore, has resulted in novel homing peptide SPU-16 for MS, designed to cross the blood-brain barrier and target damaged tissue and inflammation.

“Each of our novel therapeutics target underserved diseases with limited treatment options where we believe we can deliver quality medical care and make an impact,” Eric Weisblum, Silo’s CEO, said in the release.

Silo plans to utilize the FDA’s streamlined 505(b)(2) pathway for drug approval, the company said in the release. This approach, allowing the inclusion of external safety and efficacy data from investigational new drug applications, is expected to expedite the approval process.